Drug Name:
MIRENA Rx

Generic Name and Formulations:
Levonorgestrel 52mg; intrauterine system.
Company:
Bayer Corporation
Therapeutic Use:
Indications for MIRENA:
Intrauterine contraception for up to 5yrs.
Adult:
See full labeling. Insert into uterine cavity as directed. Reexamine 4–6 weeks after insertion and once a year thereafter, or as clinically indicated. Replace after 5 years.
Children:
Pre-menarche: not indicated.
Contraindications:
Congenital or acquired uterine anomaly. Acute or history of pelvic inflammatory disease (PID) unless subsequent intrauterine pregnancy occurred. Postpartum endometritis or septic abortion in past 3 months. Uterine or cervical neoplasia. Breast or other progestin-sensitive cancer. Uterine bleeding of unknown cause. Untreated acute cervicitis or vaginitis. Acute liver disease or liver tumor. Conditions associated with increased susceptibility to pelvic infections. Retained IUD. Pregnancy.
Warnings/Precautions:
History or risk of ectopic pregnancy. Assure suitable uterine anatomy before inserting. Risk of spontaneous abortion, miscarriage, sepsis, premature labor or delivery, congenital anomalies: remove if pregnant. Consider risks of PID before using. Exclude endometrial pathology if bleeding irregularities develop with prolonged treatment. Risk of perforation, expulsion and ovarian cysts. Increased risk of perforation in lactating women or if inserted in women with fixed retroverted uteri or during postpartum period; delay insertion a minimum ≥6wks or until involution is complete after delivery or a second trimester abortion. Remove device if any of these occur: PID, endometritis, genital actinomycosis, perforation, any sign of expulsion. Consider removal if coagulopathy, migraine, transient cerebral ischemia, severe headache, marked increase in BP, severe arterial disease (eg, stroke, MI), jaundice or uterine/cervical malignancy occurs. Nursing mothers.
Pharmacological Class:
Progestin IUD.
Interactions:
May be antagonized by CYP3A4 inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's wort, topiramate). May be potentiated by CYP3A4 inhibitors (eg, itraconazole, ketoconazole). May be potentiated or antagonized with concomitant protease inhibitors or NNRTIs. Caution with anticoagulants.
Adverse Reactions:
Menstrual bleeding pattern changes, abdominal or pelvic pain, amenorrhea, headache, migraine, genital discharge, vulvovaginitis; ectopic or intrauterine pregnancy, PID, perforation, ovarian cysts, sepsis (during insertion).
How Supplied:
System—1
Indications for MIRENA:
Treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception.
Adult:
See full labeling. Insert into uterine cavity as directed. Reexamine 4–6 weeks after insertion and once a year thereafter, or as clinically indicated. Replace after 5 years.
Children:
Pre-menarche: not indicated.
Contraindications:
Congenital or acquired uterine anomaly. Acute or history of pelvic inflammatory disease (PID) unless subsequent intrauterine pregnancy occurred. Postpartum endometritis or septic abortion in past 3 months. Uterine or cervical neoplasia. Breast or other progestin-sensitive cancer. Uterine bleeding of unknown cause. Untreated acute cervicitis or vaginitis. Acute liver disease or liver tumor. Conditions associated with increased susceptibility to pelvic infections. Retained IUD. Pregnancy.
Warnings/Precautions:
History or risk of ectopic pregnancy. Assure suitable uterine anatomy before inserting. Risk of spontaneous abortion, miscarriage, sepsis, premature labor or delivery, congenital anomalies: remove if pregnant. Consider risks of PID before using. Exclude endometrial pathology if bleeding irregularities develop with prolonged treatment. Risk of perforation, expulsion and ovarian cysts. Increased risk of perforation in lactating women or if inserted in women with fixed retroverted uteri or during postpartum period; delay insertion a minimum ≥6wks or until involution is complete after delivery or a second trimester abortion. Remove device if any of these occur: PID, endometritis, genital actinomycosis, perforation, any sign of expulsion. Consider removal if coagulopathy, migraine, transient cerebral ischemia, severe headache, marked increase in BP, severe arterial disease (eg, stroke, MI), jaundice or uterine/cervical malignancy occurs. Nursing mothers.
Pharmacological Class:
Progestin IUD.
Interactions:
May be antagonized by CYP3A4 inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's wort, topiramate). May be potentiated by CYP3A4 inhibitors (eg, itraconazole, ketoconazole). May be potentiated or antagonized with concomitant protease inhibitors or NNRTIs. Caution with anticoagulants.
Adverse Reactions:
Menstrual bleeding pattern changes, abdominal or pelvic pain, amenorrhea, headache, migraine, genital discharge, vulvovaginitis; ectopic or intrauterine pregnancy, PID, perforation, ovarian cysts, sepsis (during insertion).
How Supplied:
System—1
Clinical Pain Advisor Articles
- Does Opioid Tapering in Chronic Pain Result in Controlled Pain at Taper Completion?
- MRS May Accurately Identify Painful Disks in Chronic Low Back Pain
- Examining the Relationships Among Opioid Use, Overdose, and Suicide
- Methylprednisolone May Provide Short-Term Relief From Acute Diskogenic Sciatica
- Tobacco Users More Likely to Be Co-Prescribed Opioids With Benzodiazepines, Muscle Relaxants
- MRS May Accurately Identify Painful Disks in Chronic Low Back Pain
- Does Opioid Tapering in Chronic Pain Result in Controlled Pain at Taper Completion?
- Spinal Cord Stimulation Shows Long-Term Effectiveness for Refractory Neuropathic Pain
- Color Doppler Ultrasound for the Diagnosis of Sacroiliitis in Inflammatory Back Pain
- An Evidence-Based Road Map to Navigating the Opioid Epidemic
- OnabotulinumtoxinA Effective in Reducing Depression and Anxiety Symptoms in Chronic Migraines
- OnabotulinumtoxinA Improves Outcomes in Chronic Migraine With or Without Allodynia
- Multispecies Probiotics May Be Effective in Chronic, Episodic Migraine
- Mindfulness-Based Stress Reduction Also Benefits Chronic Pain
- Book a Ticket to Relaxation: Can a Vacation Stave Off Burnout?